74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vaxcyte Inc
Closed
SectorHealthcare
32.77 0.03
Overview
Share price change
24h
Min
32.1
Max
33.93
Income | -34M -137M |
|---|---|
EPS | -1.018 |
Employees | 414 |
EBITDA | 87M -53M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +277.07% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | -6.3B 3.9B |
|---|---|
Previous open | 32.74 |
Previous close | 32.77 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Vaxcyte Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vaxcyte Inc Forecast
Price Target
By TipRanks
277.07% upside
12 Months Forecast
Average 124.13 USD 277.07%
High 160 USD
Low 65 USD
Based on 11 Wall Street analysts offering 12 month price targets forVaxcyte Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
